Juno CEO Sold $14.6M in Stock Before Killing Toxic Drug: Suit

ByJennifer Bennett

Juno Therapeutics Inc. CEO Hans Bishop misled shareholders about a new cancer drug’s safety and then sold his stock before the company disclosed the drug’s toxic effects, according to a Jan. 3 shareholder suit.

Bishop and other executives at the biopharmaceutical company initially concealed and then blamed a companion drug for three patient deaths during Food and Drug Administration trials despite knowing the drug’s own severe neurotoxicity was to blame, according to the complaint, filed in the U.S. District Court for the District of Delaware. Bishop allegedly sold off his personal shares of Juno stock for more ...